# Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, Article 22b

Extent: E+W+S+N.I.

1. In order to determine the situations in which post-authorisation efficacy studies may be required under Articles 21a and 22a of this Directive, the Commission may adopt, by means of delegated acts in accordance with Article 121a, and subject to the conditions of Articles 121b and 121c, measures supplementing the provisions in Articles 21a and 22a.
2. When adopting such delegated acts, the Commission shall act in accordance with the provisions of this Directive.

---
Source: https://www.legislation.gov.uk/eudr/2001/83/article/22b (the official version)
Page: https://openlegislation.uk/eu-directive-2001-83/article-22b
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.